Interpretable Subgroup Discovery in Treatment Effect Estimation with
  Application to Opioid Prescribing Guidelines by Nagpal, Chirag et al.
Interpretable Subgroup Discovery in Treatment Effect
Estimation with Application to Opioid Prescribing Guidelines
Chirag Nagpal,1,2 Dennis Wei,1 Bhanukiran Vinzamuri,1 Monica Shekhar,3
Sara E. Berger,1 Subhro Das,1 and Kush R. Varshney1
1IBM Research
2Carnegie Mellon University
3IBM Global Business Services
ABSTRACT
The dearth of prescribing guidelines for physicians is one key driver
of the current opioid epidemic in the United States. In this work, we
analyze medical and pharmaceutical claims data to draw insights
on characteristics of patients who are more prone to adverse out-
comes after an initial synthetic opioid prescription. Toward this
end, we propose a generative model that allows discovery from
observational data of subgroups that demonstrate an enhanced or
diminished causal effect due to treatment. Our approach models
these sub-populations as a mixture distribution, using sparsity to
enhance interpretability, while jointly learning nonlinear predic-
tors of the potential outcomes to better adjust for confounding.
The approach leads to human-interpretable insights on discovered
subgroups, improving the practical utility for decision support.
KEYWORDS
causal treatment effect, heterogeneous treatment effect, Bayesian
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1 INTRODUCTION
The United States is in the midst of an opioid addiction epidemic.
According to estimates by the Centers for Disease Control and
Prevention (CDC), 42,000 people died from opioid overdoses in
2016 and 49,000 in 2017. Overdose mortalities specifically from
synthetic opioids, such as Fentanyl, have increased exponentially
since 1999.1 A major cause of this epidemic is overprescription of
opioids (for legitimate pain management) by physicians who lack
proper prescribing guidelines [5, 29].
One actionable insight for prescribers is characteristics of pa-
tients for whom treatment with synthetic opioids, as opposed to
natural or semi-synthetic opioids, causes a greater risk of adverse
outcomes such as long-term use and addiction than for the gen-
eral population. Toward this end, we study causal treatment effect
estimation from observational data under heterogeneity, i.e. the
phenomenon of different individuals having different responses
to the same treatment. In particular, we focus on the discovery
of subgroups of patients (really portions of a feature space) that
have enhanced or diminished treatment effects. We aim for the
discovered subgroups to be human-interpretable so that the results
can be directly used in prescribing guidelines.
We make use of the MarketScan database of medical claims and
pharmaceutical claims. Claims are a form of administrative data
that are commonly repurposed for medical studies because they
1https://www.cdc.gov/drugoverdose/data/analysis.html
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Figure 1: The heterogeneous effect subgroup discovery prob-
lem. Almost all instances receiving treatment in Z1 have a
positive outcome, while very few inZ3 do.We are interested
in recovering such latent subgroups.
capture the diagnoses, procedures, and prescriptions of patients
longitudinally. Inference of causal relationships using observational
data is challenging since counterfactual outcomes are not observed
and the treated and untreated populations may have underlying
differences that affect the outcome. However, modern machine
learning techniques provide an avenue to overcome the challenges.
To identify subgroups with different treatment effects, we hy-
pothesize that a latent variable determines the treatment effect of
each individual. Moreover, individuals with similar characteristics
belong to the same latent subgroup, resulting in similar responses
to treatment across the subgroup. Figure 1 is an abstract represen-
tation of such a phenomenon.
We propose a Bayesian network tomodel these subgroups, specif-
ically as a mixture model, along with their corresponding treatment
effects. Sparsity is induced in the learned mixture component pa-
rameters to improve interpretability. Our approach, which we name
the heterogeneous effect mixture model (HEMM), is similar in spirit
to causal rule sets for identifying subgroups with enhanced treat-
ment effect [47] but does not require hard partitions or assignments.
Moreover, we incorporate nonlinear as well as linear outcome mod-
els, which increases the expressiveness of the model to better adjust
for confounding without sacrificing the interpretability of the sub-
group definitions. We thus benefit from both the interpretability of
sparse mixture models and the representation learning capability of
neural networks. In contrast, recent works [1, 28, 42] that use neu-
ral networks or nonparametric methods to estimate heterogeneous
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treatment effects do not identify subgroups of individuals with sim-
ilar responses. While our motivating application is opioid use, the
proposed approach applies to any problem domain requiring the
discovery of subgroups with heterogeneous responses to actions.
In this spirit, we also validate our method on synthetic data and the
Infant Health and Development Program (IHDP) dataset in terms
of its heterogeneous effect estimation and subgroup identification
performance.
With respect to opioids, we provide domain expert interpretation
of the enhanced treatment effect subgroup discovered using Mar-
ketScan data, i.e. patients at higher risk of adverse outcomes after
an initial synthetic opioid prescription. Some characteristics of this
subgroup are well-known and/or reflected in CDC opioid prescrib-
ing guidelines [9]: chronic pain conditions, psychological comor-
bidities, heart disease and obesity. The presence of minor injuries
and dental/oral conditions in the subgroup can be explained by the
common practice of prescribing opioids for post-surgical or intense
acute pain. Lastly, some discovered conditions are unexpected, such
as skin infections, abscesses, and reproductive disorders.
Overall, our contributions can be summarized as follows:
i) We propose the HEMM for discovering subgroups with en-
hanced and diminished treatment effects in a potential out-
comes causal inference framework, using sparsity to enhance
interpretability.
ii) We extend the HEMM’s outcome model to include neural
networks to better adjust for confounding and develop a
joint inference procedure for the overall graphical model
and the neural networks.
iii) We demonstrate strong performance in estimating heteroge-
neous effects and identifying subgroups compared to existing
approaches.
iv) We apply the methodology to a large-scale medical claims
dataset and discover actionable patient subgroups at en-
hanced risk of adverse outcomes with synthetic opioids.
2 RELATEDWORK
There is a rich literature of data-oriented research on understanding
the patterns and risks of opioid prescribing and addiction in the
fields of medicine, medical informatics, and machine learning; some
is specifically intended to inform prescribing guidelines. Kim et al.
[22] conduct a randomized controlled trial and Neill and Herlands
[32] analyze spatiotemporal overdose event data, but a large part of
the literature works with medical claims data [3, 11, 20, 24, 35, 49]
and similar administrative data [6] as we do. However, unlike us,
none of these works focus on heterogeneous treatment effects.
The identification of subgroups with heterogeneous or enhanced
treatment effects has been addressed in the statistics literature by
building separate factual and counterfactual outcome models and
then regressing the difference of the two using another method,
e.g. a decision tree [45]. This final model can then be deployed to
identify subgroups. Within this category of approaches, Lipkovich
et al. [27] propose the subgroup identification based on differential
effect search (SIDES) algorithm, Dusseldorp and Van Mechelen
[10] propose the qualitative interaction trees (QUINT) algorithm,
and Foster et al. [12] propose the virtual twins (VT) method. We
consider empirical comparisons to these algorithms in the sequel.
Wang and Rudin [47] propose causal rule sets for discovering
subgroups with enhanced treatment effect. This is the closest to
and an inspiration for our work. That work seeks to learn discrete
human-interpretable rules predictive of enhanced treatment effect
and involves optimization by Monte Carlo methods. We consider in-
stead a mixture of experts approach with soft assignment to groups
that retains most of the interpretability but allows greater expres-
siveness and can be optimized via gradient methods. Our outcome
model (6), (7) also differs from that of [47]. Most importantly, we
allow nonlinearity in the form of neural networks whereas [47]
considers only linear models. Our model also has a single term
representing the main effect of treatment whereas [47] has three
such terms: a population average, a subgroup term that is always
active, and a subgroup term that is only active under treatment.
Recent papers have proposed estimating heterogeneous/individual
treatment effects using neural networks [28, 42] or a Bayesian
nonparametric method involving Gaussian processes [1]. These
methods rely on constructing distributional representations of the
factual and counterfactual outcomes that are similar in a statistical
sense. While these methods perform well on estimating heteroge-
nous effects, they do not identify subgroups of individuals with
similar treatment effects and characteristics and are thus less in-
terpretable. This makes the application of such methods to inform
policy decisions more difficult.
3 HETEROGENEOUS EFFECT MIXTURE
MODEL
In this section, we propose a generative mixture model for heteroge-
neous treatment effects. One way to model heterogeneity, and the
one in our proposal, is as a finite mixture of components with a dif-
ferent treatment effect model in each component (some enhanced
and some diminished). For tractability, we keep the form of the
mixtures to be the simplest possible: Gaussian-distributed for con-
tinuous covariates and Bernoulli-distributed for discrete covariates.
We encode a preference for components to involve few covariates
through a Laplace prior or a group ℓ1,2 prior on the means of the
covariates, described in Section 3.3. Section 3.4 presents a model for
the outcomes as they depend on treatment, covariates, and mixture
membership, including nonlinear dependence on the covariates.
3.1 Preliminaries
We adopt the Neyman-Rubin potential outcomes framework [39]
for causal inference. Define random variables X ∈ Rd representing
covariates and T ∈ {0, 1} as the treatment indicator. The subset
of continuous-valued covariates is denoted Xcont and the discrete
covariates (binary-valued or binarized) is denoted Xdisc. We will
sometimes refer to T = 1 as ‘the treatment’ and T = 0 as ‘the
control.’ Corresponding to the levels of treatment are two potential
outcomes Y 0 and Y 1, which are the outcomes under T = 0 and
T = 1 respectively. These outcomes can be discrete- or continuous-
valued. We are given an observational dataset of samples D =
{(xi , ti ,yi )}Ni=1 in which only one of the outcomes is observed for
each individual: if ti = 0 then yi = y0i , and if ti = 1 then yi = y
1
i .
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Figure 2: The proposed heterogeneous effect mixture model
(HEMM) in plate notation. For each instance i, (xi , ti ,yi ) are
the observed variables and zi is a latent variable that de-
termines membership in one of the K mixture components.
Each component has an associated coefficient γk that deter-
mines the main treatment effect.
Our interest lies in estimating the conditional average treatment
effect (CATE) conditioned on X, defined as
τ (X) = E[Y 1 − Y 0 | X] .
In this work, the dependence on X is mediated primarily through
subgroup membership, i.e. members of the same subgroup have sim-
ilar treatment effects. We make the standard assumptions that allow
CATE to be identifiable from observational data, namely exchange-
ability conditioned on the available covariates, T ⊥ (Y 0,Y 1) | X,
positivity of the treatment propensity, 0 < p(T = 1 | x) < 1 for
all x, and no dependence between individuals i.e. the stable unit
treatment value assumption [17, 40]. The first two assumptions are
collectively known as strong ignorability.
For the mixture model proposed in this paper, we additionally
define the latent random variable Z ∈ Z = {1, . . . ,K} to indicate
mixture membership. Both the distribution of covariates and the
treatment effect are dependent on Z as described next.
3.2 Generative Model
The generative model is presented in Figure 2 in plate notation. We
first give an overview of the distributions and then go into more
detail regarding X and Y in Sections 3.3 and 3.4.
(1) We draw a sample zi independently for each individual i
that determines the latent group membership. The prior
distribution for Z is uniform over the K groups,
Z ∼ Uniform(K). (1)
(2) Conditioned on the latent group assignment zi = k ,
(a) The xcont,i are drawn i.i.d. from a Gaussian distribution
with mean µk and covariance Σk :
Xcont | zi = k ∼ Normal(µk , Σk ). (2)
In this paper, we constrain the off-diagonal elements of
Σk to be 0 to reduce the number of parameters, although
non-diagonal covariances can be easily accommodated.
(b) The xdisc,i are drawn i.i.d. from a multivariate Bernoulli
distribution with mean πk :
Xdisc | zi = k ∼ Bernoulli(πk ). (3)
We enforce sparsity inπk in order to improve interpretabil-
ity. We describe this in detail in Section 3.3.
(3) Conditioned on the covariates xi , the treatment assignment
ti is drawn from a Bernoulli distribution whose mean is a
function of xi :
T | x ∼ Bernoulli(ρ(x)).
This corresponds to a model for treatment propensity. Note
from Figure 2 that the generative model assumes that T
is conditionally independent of Z given X. Under this as-
sumption, it will be seen in Section 4 that inference for the
propensity model can be done independently from the other
components of the generative model.
(4) Finally, an outcome sample yi is drawn from a distribution
whose mean µy is a function of the covariates xi , treatment
assignment ti , and latent group assignment zi . If Y is binary-
valued, the distribution is Bernoulli,
Y | x, t , z ∼ Bernoulli(µy (x, t , z)),
whereas if Y is continuous, the distribution is Gaussian,
Y | x, t , z ∼ Normal(µy (x, t , z),σ 2y ),
where σ 2y is the variance. The outcome model is discussed
further in Section 3.4.
3.3 Sparse Mixture Components for
Interpretability
Without further measures, the mixture component means µk and
πk learned from data may be dense, making them difficult for a
domain expert to interpret. We hypothesize that a large number of
learnedmean parameters may have small values and that promoting
sparsity through appropriate prior distributions can overcome this
problem. To this end, we experiment with two different sparsity-
promoting priors on the means πk of discrete covariates. The same
priors can be placed on the continuous covariate means µk but we
do not find this necessary in the present work.
(1) Laplace (ℓ1) Prior: We assume that the means πjk follow
zero-mean Laplace distributions and are independent across
mixture components and covariates. The negative log-likelihood
is therefore proportional to the ℓ1 norm
Ω(π ) =
∑
j ∈disc
K∑
k=1
|πjk |, (4)
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where the summation over j is restricted to the discrete
covariates.
(2) Group ℓ1,2 Prior: It may further be the case that some co-
variates are non-informative of group membership, in which
case the means πjk should be zero across all groups k and
follow the group ℓ1,2 distribution [30], similar to the group
lasso [48]. The corresponding negative log-likelihood is
Ω(π ) =
∑
j ∈disc
√√ K∑
k=1
|πjk |2. (5)
3.4 Treatment Outcome Model
We model the enhanced or diminished treatment effect in a sub-
group through the following relationships. In the case where Y is
binary, its mean is equal to the probability of Y = 1. We define the
latter using the logistic sigmoid function д to be
p(Y = 1 | x, t ,Z = k ;wt ,γk ) = д
(
f (x;wt ) + γk t
)
, (6)
where f (x;wt ) is a function of x parametrized by wt , t = 0, 1. The
term γk t represents the main effect due to treatment and the coeffi-
cientγk , i.e. the size of the effect, depends on the group membership
Z = k . The parameters wt are allowed to be different for t = 0 and
t = 1 to better account for differing covariate distributions p(x | t)
between the two treatment groups, a.k.a. selection bias. In the case
of continuous Y , we replace д with the identity function as follows:
E[Y = 1 | x, t ,Z = k ;wt ,γk ] = f (x;wt ) + γk t . (7)
The simplest choice for function f (·) is linear, i.e., two linear
functions w⊤0 x and w
⊤
1 x. In practice, however, the outcome may
have a highly nonlinear dependence on the covariates. To accom-
modate nonlinear covariate interactions and thus better adjust for
confounding, we also allow f to be a nonlinear function. In this
paper, we experiment with one- and two-hidden-layer feedforward
neural networks with ReLU activations. Outcomes under t = 0 and
t = 1 are produced by two different heads of the network, follow-
ing [21, 28, 42]. Even in the nonlinear case, the assignment of an
individual to a subgroup is still described by a mixture model and
directly interpretable in terms of the original feature representation,
thus preserving interpretability of the discovered subgroups.
It is possible to regularize the outcome models (6), (7) with ℓ2 or
ℓ1 regularization Λ(wt ), which is equivalent to adding a normal or
Laplace prior on the parameter wt . In this work however, we use
weight decay instead as discussed in Section 4.1.
4 INFERENCE
We would like to fit our proposed model to a given observational
dataset D. Denote by Θ = ({µk , Σk ,πk ,γk }Kk=1,w) the set of all
parameters of the model.
We have considered two approaches: maximizing the joint like-
lihood p(xi , ti ,yi ;Θ), and maximizing the conditional likelihood
p(yi |xi , ti ;Θ). The joint and conditional likelihoods can be related
as follows:
N∑
i=1
lnp(xi , ti ,yi ) =
N∑
i=1
[lnp(xi ) + lnp(ti | xi ) + lnp(yi | xi , ti )] .
(8)
The conditional likelihood can be further expanded as
lnp(yi | xi , ti ) = ln
( K∑
k=1
p(zi = k | xi )p(yi | xi , ti , zi = k)
)
, (9)
where we have used the conditional independence of Z andT given
X in the first factor on the right-hand side. The resulting first factor
p(zi = k | xi ) as well as the term p(xi ) in (8) depend only on the
mixture model (1)–(3), to wit p(xi ) = ∑Kk=1 p(zi = k)p(xi | zi = k)
and p(zi = k | xi ) = p(zi = k)p(xi | zi = k)/p(xi ). The second
factor on the right-hand side of (9) depends only on the outcome
model (6), (7). The remaining term p(ti | xi ) in (8) depends on the
propensity model. Since this is the only place where the propensity
model appears, its inference is separable from the remainder of the
problem, as claimed in Section 3.2. We do not discuss propensity
modeling further as it is not the focus of this work.
Although maximizing the joint likelihood (8) results in some
closed-form expressions and accordingly easier inference of param-
eters, we have observed in practice that maximizing the conditional
likelihood (9) has superior performance in estimating the poten-
tial outcomes Y t and treatment effects. Therefore, we pursue this
discriminative approach in this work. We do however include the
sparsity-inducing prior on the parameters πk discussed in Sec-
tion 3.3. The full objective function is therefore
N∑
i=1
lnp(yi | xi , ti ;Θ) − λΩ(π ), (10)
where λ controls the strength of the prior.
4.1 Evidence Lower Bound (ELBO)
Optimization
Instead of optimizing the conditional log-likelihood in (10) directly
using a gradient method, we choose to lower bound the likelihood
with a variational approximation, more commonly known as the
Evidence Lower Bound (ELBO) [2]. For any variational distribution
q(Z ) over the latent variable Z , we have
lnp(yi | xi , ti ;Θ) = ln
K∑
k=1
p(yi , zi = k | xi , ti ;Θ)
= ln
(
Eq
[p(yi , zi | xi , ti ;Θ)
q(Z )
] )
≥ Eq
[
ln p(yi , zi | xi , ti ;Θ)
q(Z )
]
(11)
using Jensen’s inequality. Now, replacing q(Z ) with p(zi |xi ;Θ) and
using (9) (and Z ⊥ T | X from Figure 2), we obtain
ELBO(yi , xi , ti ;Θ) =
K∑
k=1
p(zi = k | xi ;Θ) lnp(yi | xi , ti , zi = k ;Θ).
(12)
We hence substitute (12) in place of lnp(yi | xi , ti ;Θ) in (10)
and proceed to maximize the objective function using the Adam
gradient method [23], a variant of stochastic gradient descent that
is a popular choice for non-convex functions like neural networks.
The same method is used for both linear and nonlinear f in (6),
(7). As noted above, the first factor p(zi = k | xi ;Θ) in (12) depends
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only on the mixture model parameters in (1)–(3) while the second
factor depends only on the outcome model parameters in (6), (7).
We enable “weight decay” [26] on the parameters wt as a form of
regularization. For tractability, we compute the ELBO only over
a fixed-size mini-batch of the data before each parameter update.
Additional details on the algorithm and parameter initialization can
be found in Appendices A and B in the supplement.
We also considered an expectation-maximization (EM) algorithm
tomaximize (10) as an alternative to ELBO. Our experience however
was that ELBO provided better heterogeneous effect estimates in
terms of the metric reported in Section 6.2.
5 DATASET DESCRIPTIONS
We demonstrate the performance of HEMM on a synthetic dataset,
the semi-synthetic Infant Health andDevelopment Program (IHDP)
dataset, and a real-world dataset on opioids. These datasets are de-
scribed further below.
Synthetic: We take X = (X0,X1) ∈ R2 and sample it from a
uniform distribution overX = [0, 1]2. In order to simulate the selec-
tion bias inherent in observational studies, the treatment variable
depends on X asT ∼ Bernoulli(0.4) for x0 < 0.5 and Bernoulli(0.6)
for x0 > 0.5. The potential outcomes Y 0 and Y 1 are also Bernoulli
with means given by the functions of X shown in Figure 3a. The fig-
ure shows that p(Y 1 = 1 |X) > p(Y 0 = 1 |X), i.e. treatment increases
the probability of positive outcome. Note that under the conditional
exchangeability assumption we have p(Y t = 1 | X) = p(Y = 1 | T =
t ,X). We model the effect of the confounders X by assigning higher
probability to the upper triangular region of X. This together with
the distribution of T imply that individuals who are more likely
to have positive outcome regardless of treatment (upper triangle)
are also more likely to receive treatment (right half-square). Lastly,
we model the enhanced treatment effect group as a circular region
S = {x : ∥x −c ∥2 < r }, where p(Y 1 = 1 | S) > p(Y 1 = 1 | X\S). We
set c = ( 12 , 12 ) and r = 14 . A total of 1000 samples (xi , ti ,yi ) were
generated as described above.
IHDP (Semi-Synthetic): The IHDP dataset has gained popular-
ity in the causal inference literature dealing with heterogenous
treatment effects [1, 18, 28, 42]. The original data includes 25 real
covariates and comes from a randomized experiment to evaluate the
benefit of IHDP on IQ scores of three-year-old children. A selection
bias was introduced by removing some of the treated population,
thus resulting in 608 control patients and 139 treated (747 total). The
outcomes were simulated using the standard non-linear ‘Response
Surface B’ as described in [18].
Opioid: We sampled a sub-population consisting of healthcare
claims for five million patients from the MarketScan Commercial
claims database. These claims describe patients’ medical histories,
including both inpatient admissions and outpatient services. Di-
agnoses, procedures, prescriptions and dosages are recorded. We
follow the cohort selection procedure outlined in Zhang et al. [49]
to filter patients based on several criteria.
For each patient in our final cohort, we create a feature vector
that includes basic demographic information such as age, gender
Total Covariate Dimension 1226 3 Continuous,
1223 Binary
ICD-9 Diagnostic Codes 1013 Binary
CPT Procedure Codes 171 Binary
Hand-Crafted Comorbidities 41 Binary
Daily Morphine Equivalent, 3 Continuous
Total Number of Visits, Age
Addicted Not-Addicted Total
(Y=1) (Y=0)
Treated (T=1) 2060 19983 22043
Control (T=0) 7269 176156 183425
Total 9329 196139 205468
Table 1: Opioid Dataset Statistics
and geographic region. We also included a predefined set of pro-
cedures along with diagnostic codes which are associated with
opioids and/or addiction, based on input from a physician.
We label all patients who received addiction diagnoses and pa-
tients who continued use of opioids for more than one year after
the initial prescription as belonging to the positive (adverse out-
come) class. Patients who discontinued opioid use within one year
of initial treatment were labeled as negative. We use the terms
“addicted” and “not addicted” as shorthand for these outcomes. Pa-
tients prescribed natural or semi-synthetic opioids are considered
the control group, whereas patients administered synthetic opioids
are considered the treated group. Table 1 summarizes the basic
statistics of this dataset.
6 EXPERIMENTAL RESULTS
We evaluated the proposed HEMM quantitatively on two tasks,
prediction of heterogeneous treatment effects and identification
of subgroups with enhanced or reduced effect. These results are
discussed in Sections 6.2 and 6.3 respectively in comparison to ex-
isting methods, focusing on those that also estimate heterogeneous
effects in an interpretable manner. Methods used in the comparison
are described in Section 6.1 and parameter selection details are in
Appendix B. In Section 6.4, we provide qualitative results for the
Opioid dataset on the features the model discovers as characteris-
tics of “at-risk” individuals, i.e. those in enhanced effect subgroups.
6.1 Algorithms in Comparison
We have considered Virtual Twins (VT) [12], QUINT [10], and
SIDES [27] among methods that identify subgroups with different
treatment effects. We implemented two versions of VT in which
the treatment effect is modeled by a decision tree classifier (VT-C)
or regressor (VT-R). For VT-C, to better represent the continuous-
valued treatment effect (which is a difference in probabilities even if
Y is binary), we use a collection of decision tree classifiers obtained
by applying different thresholds to the treatment effect.
For QUINT and SIDES, we utilized the standard R implementa-
tions and performed extensive hyperparameter tuning. However
both QUINT and SIDES failed to recover any subgroups on Syn-
thetic andOpioid and we thus did not consider them further. For
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(a) Potential outcome probabilities p(Y 0 = 1 | X) (con-
trol) and p(Y 1 = 1 | X) (treated). Treatment propensity
is greater to the right of the black dashed line, while the
blue dashed line denotes the regionwith enhanced effect.
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Figure 3: Synthetic dataset and enhanced effect subgroups discovered by HEMM and Virtual Twins (VT).
QUINT, the likely reason is that its assumption of a subgroup with
diminished effect is not always met, whereas for SIDES, there may
be a numerical issue in how it discretizes continuous covariates.
In terms of methods that only predict heterogeneous effects and
do not identify subgroups, we also compare our method with some
common approaches in Table 2. Here Linear-1 corresponds to a
single ordinary least squares (for continuous outcomes) or logistic
regression (for binary outcomes) for both factual and counterfac-
tual outcomes. In the case of Linear-2, we fit two separate linear
models to the control and treated populations to better accommo-
date selection bias and confounding. The other baselines, k-NN, GP,
and CFRF are non-parametric versions of this approach where the
estimators of the factual and counterfactual outcomes are k-nearest
neighbours, Gaussian processes with a linear kernel and Random
Forests respectively.
6.2 Heterogeneous Effect Estimation
We first evaluate our performance on estimation of the CATE
(E[Y 1−Y 0 |X]). A popular metric for this evaluation is the Precision
in Estimating Heterogenous Effects (PEHE). The PEHE is defined as
PEHE = 1
n
n∑
i=1
(
f1(xi) − f0(xi ) − E[Y 1 − Y 0 | X = xi ]
)2
.
Here f1(·) and f0(·) are the estimated potential outcomes under
treatment and control, respectively.
Table 2 compares the performance of HEMM against themethods
described in Section 6.1 on both in-sample PEHE (corresponding
to a retrospective study) computed on the training data, and out-
of-sample PEHE computed on held-out test data. HEMM-MLP and
HEMM-Lin refer to the proposed approach with f in (6), (7) as a
multilayer perceptron and linear function respectively to model the
effect of confounders on the outcome.
HEMM consistently outperforms these standard causal inference
baselines. GP and Linear-2 perform close to HEMM on Synthetic.
We noticed that when a larger sample of data points is available
to VT-R, its performance increases dramatically. However, its per-
formance drops in higher-dimensional settings as in the case of
IHDP and Opioid; this is expected with methods involving non-
parametric regression.
Synthetic IHDP
In-sample Out-Sample In-sample Out-Sample
HEMM-MLP 0.101 ± 10−3 0.102 ± 10−3 1.6 ± 0.10 1.8 ± 0.10
HEMM-Lin 0.116 ± 10−3 0.116 ± 10−3 2.8 ± 0.32 2.9 ± 0.33
Linear-1 0.278 ± 10−3 0.278 ± 10−3 7.9 ± 0.46 7.9 ± 0.47
Linear-2 0.106 ± 10−3 0.107 ± 10−3 2.3 ± 0.18 2.4 ± 0.21
k-NN 0.210 ± 10−3 0.210 ± 10−3 3.2 ± 0.12 4.2 ± 0.22
GP 0.106 ± 10−3 0.107 ± 10−3 2.1 ± 0.11 2.3 ± 0.14
CFRF 0.146 ± 10−3 0.142 ± 10−3 2.7 ± 0.31 3.3 ± 0.72
VT-R 0.130 ± 10−3 0.130 ± 10−3 2.5 ± 0.26 2.9 ± 0.51
Table 2:
√
PEHE values in estimating heterogeneous effects.
Error represents 95% confidence interval of multiple Monte
Carlo initializations.
6.3 Subgroup Identification
Synthetic: In the case of synthetic data, the subgroup with en-
hanced treatment effect is known. We first visualize the perfor-
mance of HEMM and VT in identifying this subgroup. For HEMM-
Lin, Figure 3b shows the estimated probability p(Z |X) of belonging
to the enhanced effect subgroup evaluated on the test set. The true
circular region is recovered well. Figures 3c and 3d plot the VT-C
and VT-R predictions of CATE on the test set. For VT-C, the pre-
diction represents an average over the collection of decision tree
classifiers, while for VT-R, it is simply the output of the decision
tree regressor. While the difficulty in reproducing the circular shape
is expected for decision trees, the enhanced effect estimates are also
less uniform than in Figure 3b.
We also evaluate subgroup identification more quantitatively by
treating it as a problem of classifying whether or not points in the
test set belong to the enhanced effect subgroup. ROC curves may
then be plotted as in Figure 4a. For HEMM, the ROC is traced by
varying the threshold on the probability p(Z | X) of being in the
enhanced effect subgroup (shown in Figure 3b). Similarly for VT-C
and VT-R, the threshold on the CATE estimates (Figures 3c and
3d) is varied. HEMM has higher ROCs than VT on this example, in
line with Figures 3b–3d. There is little difference between HEMM-
Lin and HEMM-MLP since the dependence on the covariates X in
Figure 3a is simple and complex adjustment is not needed.
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Figure 4: Performance of the proposed HEMM and Virtual Twins on the subgroup discovery task. For Synthetic data, we
have access to ground truth labels for the enhanced treatment effect group and hence compare performance using the ROC.
For the IHDP and Opioid datasets, we compare average treatment effect (ATE) estimates within the identified subgroup as a
function of subgroup size (as a fraction of the population).
IHDP and Opioid: For the other two datasets, we conduct a rel-
ative comparison with VT since we lack data on ground truth
subgroups. The evaluation involves two steps. First, we assign indi-
viduals to an enhanced effect subgroup of varying size. (The same
procedure can be used for a diminished effect subgroup but we omit
the results due to space.) For HEMM, we choose the subgroup k
with the largest main effect γk and vary the threshold applied to
the corresponding membership probability p(Z = k | X) returned
by the model. For VT-C and VT-R, we vary the threshold applied to
the CATE estimates, either the composite estimate of the decision
tree classifiers or the regressor estimate, the same quantities as for
the synthetic data. In the second step, we build a propensity score
model (an estimator of treatment propensity p(T = 1|X)) to esti-
mate the average treatment effect (ATE) conditioned on belonging
to the enhanced treatment effect subgroup defined in the first step.
For the propensity score model e(X), we fit a random forest, for
which parameter tuning is performed on the dev set. We then use
the inverse probability of treatment weighting (IPTW) estimator
[19] of the ATE within a subgroup S as follows:
τˆS =
1
|S|
∑
i ∈S
(
yi ti
e(Xi ) −
yi (1 − ti )
1 − e(Xi )
)
. (13)
IPTW estimation is used for both HEMM- and VT-defined sub-
groups to be consistent.
Figures 4b and 4c plot subgroup ATE versus subgroup size (as a
fraction of the population) as the threshold for subgroup assignment
is varied. When the subgroup is the entire population at size 1.0,
all curves meet at the population ATE (dashed line). Since we have
selected the enhanced effect subgroup, the curves are then expected
to increase as the subgroup is restricted to individuals with larger
treatment effects. The fact that this increase is nearly monotonic for
HEMM-MLP is evidence for the validity of the discovered subgroup,
since the IPTW estimator used here is an independent check on the
treatment effect model (6), (7) used by HEMM. Compared to VT,
the subgroups identified by HEMM-MLP have higher ATE. This
suggests that for a given subgroup size, HEMM-MLP is better at
grouping together individuals with more enhanced effects. HEMM-
Lin on the other hand displays contrasting performances. On IHDP
in Figure 4b, the estimated ATE actually decreases for subgroup
sizes less than 0.5, likely due to the inadequacy of a linear model to
adjust for confounding and accurately estimate CATE. In Figure 4c
however, the ATE does increase monotonically and faster than for
VT.
6.4 Interpretation of the Opioid Enhanced
Effect Subgroup
We now turn our focus to the motivating application of opioids
and analyze key characteristics of the enhanced effect subgroup,
i.e. those patients at greater risk of adverse outcomes when treated
initially with synthetic opioids. To interpret these features, we
collaborated with a subject matter expert (SME) with a PhD in
cognitive neuroscience and a clinical research emphasis in chronic
pain conditions and treatments, including opioids. Table 3 shows
the top features of the enhanced effect subgroup as identified by
HEMM-MLP. The features are organized by general bodily system
and sorted in descending order of prevalence relative to the other
subgroup (see table caption); the selection of 3 features in each
system was arbitrary and chosen primarily for simplicity and space
constraints.
Patients with a history of chronic conditions in general, as well
as chronic pain conditions more specifically, are at an increased risk
for addiction. Many of the chronic conditions in Table 3, e.g. heart
disease (circulatory system), psoriasis (integumentary system), and
BMI/obesity (nutrition) also appear in the CDC opioid prescribing
guidelines [9] or have extensive literature linking them to increased
risk for long-term pain, either intrinsic to the condition or due to
needed medical procedures that are more likely to expose patients
to opioids [14]. For example, numerous papers show a link between
increased body-mass index (BMI) and increased pain intensity and
duration (with anti-correlations between BMI and pain recovery)
[33], and obesity has also been associated with higher initial opi-
oid doses [25]. Additionally, the chronic nutritional deficiencies
and imbalances shown in Table 3 have been linked to acute but
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Musculoskeletal System Nervous System
1.0 spinal curve (kyphosis, lordosis, scoliosis) 1.0 extrapyramidal diseases/movmt. disorders
1.0 ankle fracture 1.0 idiopathic peripheral neuropathies
1.0 sprains/strains of hand and wrist 1.0 headaches
Integumentary System Endocrine System
1.0 cellulitis and abscess of finger and toe .70 simple and unspecified goiter
1.0 local skin infections .67 other endocrine disorders
1.0 psoriasis and similar disorders .65 thyrotoxicosis with or without goiter
Reproductive System Digestive and Excretory Systems
1.0 female infertility .71 benign neoplasm of intestinal tract
.82 testicular dysfunction .69 inguinal hernia
.82 disorders of penis .58 diverticulitis
Circulatory System Immune System
1.0 hypertensive heart disease .56 immunization
.79 other disorders of circulatory system .54 strep throat and scarlet fever
.70 cardiac dysrhythmias .52 bacterial infections in other conditions
Nutrition Visual System
1.0 BMI .87 keratitis
1.0 b-complex deficiency .60 other disorders of eye (epi)scleritis
.71 disorder of electrolyte/acid-base balance .57 visual disturbances
Auditory System Psychology
.53 vertiginous syndrome/vestibular disorder 1.0 suspected mental health condition
.50 otitis media/eustachian tube disorders .58 adjustment reaction
.44 disorders of pinna and mastoid process .55 nondependent abuse of drugs
Digestive System (upper/oral) Respiratory System
.77 hernia, abdominal cavity w/o obstruction 1.0 other diseases of respiratory tract
.77 dentofacial anomalies of jaw .74 deviated nasal septum
.76 diseases of oral soft tissues .69 influenza
Table 3: Top features of the enhanced effect subgroup k dis-
covered byHEMM-MLP on theOpioid dataset. The numbers
are the ratios πjk/
∑
k ′ πjk ′ , where 1/2 represents no increase
in prevalence over the other subgroup (K = 2).
intense muscle spasms as well as peripheral polyneuropathies and
paresthesias (see e.g. [31]), pain disorders which also show up as
increased risk factors (nervous system).
Regarding chronic pain conditions, patients with a history of
abnormal spinal curvatures (which can produce low back pain and
neuropathy), idiopathic peripheral neuropathies, and headaches
(musculoskeletal and nervous systems) are at increased risk for
addiction. These are not surprising as they non-opioid therapies
such as non-steroidal anti-inflammatory drugs (NSAIDs), steroids,
or common procedures and surgeries (e.g. joint replacement or
local injections) [7]. They involve pain that may be severely in-
tense or debilitating, sometimes unpredictable or idiopathic, and
often non-specific or diffuse (pain is referred, not well localized,
or difficult to describe) and thus require a cocktail of prescription
medications or invasive procedures, increasing the likelihood of
exposure to opioids [36, 38, 46]. The intensity, duration, and non-
specificity of pain may also be a reason why digestive excretory,
digestive (upper/oral), and reproductive conditions also show up
as moderately strong features in Table 3. These diagnoses may ei-
ther directly result in acute or chronic non-somatic visceral pain
(hernia, diverticulitis) [8] or relate to conditions with chronic vis-
ceral pain (e.g. female infertility may be secondary to endometriosis
or pelvic inflammatory diseases). Opioids are widely utilized for
such visceral pain conditions [13], although often in short duration
due to adverse events. Notably, some minor injuries causing acute
or procedure-related pain (ankle fractures or hand/wrist sprains –
musculoskeletal system) also feature prominently, as do features
related to the mouth (dentofacial abnormalities and soft oral tissues
– digestive system (upper/oral)). This is also expected given that
opioids are most commonly prescribed for post-surgical or intense
acute pain [4, 15]; regarding dental procedures specifically, previous
research suggests that a substantial proportion of adults are first
exposed to opioids through dental procedures [41].
Another expected finding was that individuals with psychologi-
cal comorbidities (mental health conditions) also have high proba-
bility of belonging to the enhanced response group, with individuals
participating in psychotherapy having reduced risk of addiction
(psychotherapy was among the lowest-scored features and hence
not shown in the table). Substantial research has already linked
mental illness with opioid misuse [14, 38, 46]. Although adjust-
ment reaction (psychology) appears with a lower score in Table 3,
it encompasses reactions to trauma, episodic emotional disorders,
and chronic anxiety that have been shown to be comorbid with
many of the chronic diagnoses and pain conditions discussed above
[14, 38, 46] and have also been linked with increased opioid dosages
[16]. Similarly, nondependent abuse of drugs also has a lower score
but it is well known that opioid dependence and addiction are
associated with polysubstance use and abuse [37, 43].
A small subset of features with high scores were more challeng-
ing to interpret, likely because they pick up on subtle relationships
between existing clinical variables or hidden variables. For example,
electrolyte imbalances (nutrition) occur often and in many situa-
tions, making it difficult to speculate on why they were a top feature
for risk propensity. Likewise, skin infections and abscesses (integu-
mentary system) also are common and non-specific. However, it is
possible that these features are secondary symptoms of important
risk features. For instance, electrolyte imbalances are commonly
seen in alcoholism and substance use disorders [34], as are skin
infections and abscesses [44].
Based on this initial overview, the SME judged the majority of
the identified features to be scientifically meaningful with potential
clinical utility for future prescribing guidelines. In summary, acute
or chronic conditions that put patients at increased risk for initial
exposure to opioids, via acute procedures or comorbid prolonged
intense pain, both increased a patient’s addiction likelihood. Co-
morbid mental health disorders, particularly those related to stress
or trauma and substance abuse also put individuals at greater risk
for future opioid addiction.
7 CONCLUSION
We presented a Heterogeneous Effect Mixture Model (HEMM) for
inferring subgroups of individuals that exhibit an enhanced ef-
fect caused by treatment. Our work contrasts with existing het-
erogeneous effect estimation methods as we learn interpretable
subgroups using soft assignments while retaining expressiveness
in the model. The latter is attributed to the capabilities of neural
networks, used here to adjust for confounding. We evaluated the
performance of HEMM on a synthetic dataset, the semi-synthetic
IHDP dataset, and a large real-world healthcare claims dataset
(Opioid).
We additionally conducted qualitative analysis of the results ob-
tained byHEMM on theOpioid dataset. Some of our findings are in
accordance with existing CDC opioid prescribing guidelines. How-
ever, our interpretations are preliminary and future analyses are
needed to better understand these features and their relationships.
Interpretable Subgroup Discovery in Treatment Effect Estimation with Application to Opioid Prescribing Guidelines
A longer-term goal is to translate such insights into a policy white
paper on data-driven, causally-valid opioid prescribing guidelines.
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A PARAMETER INITIALIZATION
Gradient based optimization strategies can be subject to local min-
ima and hence their performance is dependent on parameter initial-
ization. To initialize the model with ‘good’ values ensuring better
convergence, we set the mean for each component, µk and πk ,
equal to the sample mean of the entire data, i.e. µ0k =
1
N
∑
i xcont,i ,
π0k =
1
N
∑
i xdisc,i , and the covariance of every component to
Σ0k = diag(σ ), where σ is a vector consisting of the sample vari-
ances of the continuous covariates Xcont. We pre-train the parame-
ters wt in the outcome model (6) using standard cross-entropy loss
without the subgroup and treatment assignment term γk t . Finally,
we initialize the treatment coefficients, γk , randomly with positive
values for all k .
B MODEL FITTING
Our implementation of HEMM has two free parameters, the number
of groups K and the strength of the sparsity prior, λ.
For the Opioid dataset we divide the dataset into 3 parts with
70% as train for model training, 10% as dev for parameter tuning,
and 20% as test for evaluation. The partition is done so that the
joint distribution of outcome and treatment is approximately the
same in the 3 sets: pTRAIN(Y ,T ) ≈ pTEST(Y ,T ) ≈ pDEV(Y ,T ). For
IHDP we use the stnadard 80/20 train/test split as is popular in
literature.
We perform a grid search overK ∈ {2, 3, 4} and λ ∈ {0, 10−3, 10−2, 10−1}.
For each (K , λ) pair, we perform 5 runs with randomly initialized
values of the treatment coefficients γk . All other parameters are
initialized as described in Section A. For Adam, we use a step size of
10−4 and mini-batch sizes of 10, 20 & 1000 for Synthetic, IHDP,
and Opioid respectively, and stop parameter update if the ELBO
on the dev is lower at the end of an epoch. We also search over
the space of models where the outcome and counterfactual have
the same or different parameterisation based on treatment assign-
ment. From all the (K , λ) pairs and random initializations above,
we select the model that has the best performance on the dev set in
predicting the outcome yi , in terms of the Area Under the Receiver
Operating Characteristic (AU-ROC).
For the Synthetic dataset, we simply set K = 2 and λ = 0. In
this case there is no need for a dev set and the data is split 50/50
between train and test.
Figure 5 shows the percentage of parameters πjk equal to zero
(labeled “Sparsity” and “Group Sparsity” in the plots) across all
groups k for different values of (K , λ) and averaged over random
initializations. It is clear that larger values of the prior strength
parameter λ result in sparser solutions.
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Figure 5: Effect of the prior strength λ for Laplace (ℓ1, left)
and group ℓ1,2 (right) priors and different values of K .
REFERENCES
[1] Ahmed M Alaa and Mihaela van der Schaar. 2017. Bayesian inference of indi-
vidualized treatment effects using multi-task gaussian processes. In Advances in
Neural Information Processing Systems. 3424–3432.
[2] David M Blei, Alp Kucukelbir, and Jon D McAuliffe. 2017. Variational inference:
A review for statisticians. J. Amer. Statist. Assoc. 112, 518 (2017), 859–877.
[3] Gabriel A. Brat, Denis Agniel, Andrew Beam, Brian Yorkgitis, Mark Bicket, Mark
Homer, Kathe P. Fox, Daniel B. Knecht, Cheryl N McMahill-Walraven, Nathan
Palmer, and Isaac Kohane. 2018. Postsurgical Prescriptions for Opioid Naive
Patients and Association with Overdose and Misuse: Retrospective Cohort Study.
BMJ 360 (Jan. 2018), j5790.
[4] Chad M. Brummett, Jennifer F. Waljee, Jenna Goesling, Stephanie Moser, Paul
Lin, Michael J. Englesbe, Amy S. B. Bohnert, Sachin Kheterpal, and Brahmajee K.
Nallamothu. 2017. New Persistent Opioid Use After Minor and Major Surgical
Procedures in US Adults. JAMA Surg. 152, 6 (2017), e170504.
[5] Robert M Califf, JanetWoodcock, and Stephen Ostroff. 2016. A proactive response
to prescription opioid abuse. New England J. Med. 374, 15 (2016), 1480–1485.
[6] Zhengping Che, Jennifer St. Sauver, Hongfang Liu, and Yan Liu. 2017. Deep
Learning Solutions for Classifying Patients on Opioid Use. In AMIA Annu. Symp.
Proc. 525–534.
[7] Leslie J. Crofford. 2013. Use of NSAIDs in Treating Patients with Arthritis.
Arthritis Res. Ther. 15, Suppl. 3 (July 2013), S2.
[8] Mellar P. Davis. 2012. Drug Management of Visceral Pain: Concepts from Basic
Research. Pain Res. Treat. 2012 (2012), 265605.
[9] Deborah Dowell, Tamara M Haegerich, and Roger Chou. 2016. CDC guideline for
prescribing opioids for chronic pain—United States, 2016. JAMA 315, 15 (2016),
1624–1645.
[10] Elise Dusseldorp and Iven Van Mechelen. 2014. Qualitative Interaction Trees: A
Tool to Identify Qualitative TreatmentâĂŞSubgroup Interactions. Stat. Med. 33, 2
(Jan. 2014), 219–237.
[11] Mark J. Edlund, Diane Steffick, Teresa Hudson, Katherine M. Harris, and Mark
Sullivan. 2007. Risk Factors for Clinically Recognized Opioid Abuse and Depen-
dence among Veterans using Opioids for Chronic Non-Cancer Pain. Pain 129, 3
(June 2007), 355–362.
[12] Jared C Foster, Jeremy MG Taylor, and Stephen J Ruberg. 2011. Subgroup identi-
fication from randomized clinical trial data. Stat. Med. 30, 24 (2011), 2867–2880.
[13] G. F. Gebhart, Xin Su, Shailen Joshi, N. Ozaki, and J. N. Sengupta. 2000. Peripheral
Opioid Modulation of Visceral Pain. Ann. N. Y. Acad. Sci. 909, 1 (Jan. 2000), 41–50.
[14] Jason M. Glanz, Komal J. Narwaney, Shane R. Mueller, Edward M. Gardner, Su-
san L. Calcaterra, Stanley Xu, Kristin Breslin, and Ingrid A. Binswanger. 2018.
Prediction Model for Two-Year Risk of Opioid Overdose Among Patients Pre-
scribed Chronic Opioid Therapy. J. Gen. Intern. Med. 33, 10 (Oct. 2018), 1646–1653.
[15] Calista M. Harbaugh, Jay S. Lee, Hsou Mei Hu, Sean Esteban McCabe, Terri
Voepel-Lewis, Michael J. Englesbe, Chad M. Brummett, and Jennifer F. Waljee.
2018. Persistent Opioid Use Among Pediatric Patients After Surgery. Pediatrics
144, 1 (Jan. 2018), e20172439.
[16] G. T. T. Helmerhorst, A.-M. Vranceanu, M. Vrahas, M. Smith, and D. Ring. 2014.
Risk Factors for Continued Opioid Use One to Two Months After Surgery for
Musculoskeletal Trauma. J. Bone & Joint Surgery 96, 6 (March 2014), 495–499.
[17] Miguel A. Hernán and James M. Robins. 2018. Causal Inference. Chapman &
Hall/CRC, Boca Raton, FL, USA. Forthcoming.
[18] Jennifer L Hill. 2011. Bayesian nonparametric modeling for causal inference.
Journal of Computational and Graphical Statistics 20, 1 (2011), 217–240.
[19] Guido W Imbens. 2004. Nonparametric estimation of average treatment effects
under exogeneity: A review. Review of Economics and statistics 86, 1 (2004), 4–29.
[20] Anupam B Jena, Dana Goldman, Leonard D Schaeffer, Lesley Weaver, and Pinar
Karaca-Mandic. 2014. Opioid Prescribing by Multiple Providers in Medicare:
Retrospective Observational Study of Insurance Claims. BMJ 348 (Feb. 2014),
g1393.
Nagpal, et al.
[21] Fredrik Johansson, Uri Shalit, and David Sontag. 2016. Learning representations
for counterfactual inference. In Proc. Int. Conf. Mach. Learn. 3020–3029.
[22] Nayoung Kim, Jonas L. Matzon, Jack Abboudi, Christopher Jones, William Kirk-
patrick, Charles F. Leinberry, Frederic E. Liss, Kevin F. Lutsky, Mark L. Wang,
Mitchell Maltenfort, and Asif M. Ilyas. 2016. A Prospective Evaluation of Opioid
Utilization After Upper-Extremity Surgical Procedures: Identifying Consumption
Patterns and Determining Prescribing Guidelines. J. Bone Joint Surg. 98, 20 (Oct.
2016), e89.
[23] Diederik P Kingma and Jimmy Ba. 2014. Adam: A method for stochastic opti-
mization. arXiv preprint arXiv:1412.6980 (2014).
[24] Michael P. Klueh, Hsou M. Hu, Ryan A. Howard, Joceline V. Vu, Calista M. Har-
baugh, Pooja A. Lagisetty, Chad M. Brummett, Michael J. Englesbe, Jennifer F.
Waljee, and Jay S. Lee. 2018. Transitions of Care for Postoperative Opioid Pre-
scribing in Previously Opioid-Naïve Patients in the USA: a Retrospective Review.
J. Gen. Intern. Med. in press (2018).
[25] A. M. Kobus, D. H. Smith, B. J. Morasco, E. S. Johnson, X. Yang, A. F. Petrik, and
R. A. Deyo. 2012. Correlates of higher-dose opioid medication use for low back
pain in primary care. J. Pain 13, 11 (Nov. 2012), 1131–1138.
[26] Anders Krogh and John A Hertz. 1992. A simple weight decay can improve
generalization. In Advances in neural information processing systems. 950–957.
[27] Ilya Lipkovich, Alex Dmitrienko, Jonathan Denne, and Gregory Enas. 2011. Sub-
group identification based on differential effect search âĂŤ– a recursive parti-
tioning method for establishing response to treatment in patient subpopulations.
Stat. Med. 30, 21 (2011), 2601–2621.
[28] Christos Louizos, Uri Shalit, Joris M Mooij, David Sontag, Richard Zemel, and
Max Welling. 2017. Causal effect inference with deep latent-variable models. In
Adv. Neur. Inf. Process. Syst. 6446–6456.
[29] Martin A Makary, Heidi N Overton, and Peiqi Wang. 2017. Overprescribing is
major contributor to opioid crisis. BMJ 359 (2017), j4792.
[30] Benjamin M. Marlin, Mark Schmidt, , and Kevin P. Murphy. 2009. Group Sparse
Priors for Covariance Estimation. In Proc. Conf. Uncertainty Artif. Intell.Montreal,
Canada, 383–392.
[31] Barbara Mostacci, Rocco Liguori, and Arrigo F. Cicero. 2018. Nutraceutical
Approach to Peripheral Neuropathies: Evidence from Clinical Trials. Current
Drug Metabolism 19, 5 (2018), 460–468.
[32] Daniel B. Neill andWilliam Herlands. 2018. Machine Learning for Drug Overdose
Surveillance. J. Tech. Human Serv. 36, 1 (Jan. 2018), 8–14.
[33] Akiko Okifuji and Bradford D. Hare. 2015. The association between chronic pain
and obesity. J. Pain Res. 8 (2015), 399–408.
[34] Biff F. Palmer and Deborah J. Clegg. 2017. Electrolyte disturbances in patients
with chronic alcohol-use disorder. New England J. Med. 377, 14 (2017), 1368–1377.
[35] Stephen T. Parente, Susan S. Kim, Michael D. Finch, Lisa A. Schloff, Thomas S.
Rector, Raafat Seifeldin, and J. David Haddox. 2004. Identifying Controlled
Substance Patterns of Utilization Requiring Evaluation Using Administrative
Claims Data. Am. J. Managed Care 10, 11 (Nov. 2004), 783–790.
[36] Pravinkumar R. Patil, Jonathan Wolfe, Qayyim Said, Jeremy Thomas, and
Bradley C. Martin. 2015. Opioid Use in the Management of Diabetic Periph-
eral Neuropathy (DPN) in a Large Commercially Insured Population. Clin. J. Pain
31, 5 (May 2015), 414–424.
[37] Joseph V. Pergolizzi, Christopher Gharibo, Steven Passik, Sumedha Labhsetwar,
Robert Taylor, Jason S. Pergolizzi, and Gerhard Müller-Schwefe. 2012. Dynamic
risk factors in the misuse of opioid analgesics. J. Psychosomatic Res. 72, 6 (2012),
443–451.
[38] A. Rosenblum, L. A. Marsch, H. Joseph, and R. K. Portenoy. 2008. Opioids and the
treatment of chronic pain: controversies, current status, and future directions.
Exp. Clin. Psychopharmacol. 16, 5 (Oct. 2008), 405–416.
[39] Donald B Rubin. 1974. Estimating causal effects of treatments in randomized and
nonrandomized studies. J. Edu. Psych. 66, 5 (1974), 688–701.
[40] Donald B. Rubin. 1986. Which Ifs Have Causal Answers. J. Am. Stat. Assoc. 81,
396 (1986), 961–962.
[41] Alan R. Schroeder, Melody Dehghan, Thomas B. Newman, Jason P. Bentley, and
K. T. Park. in press. Association of Opioid Prescriptions From Dental Clinicians
for US Adolescents and Young Adults With Subsequent Opioid Use and Abuse.
JAMA Intern Med. (in press).
[42] Uri Shalit, Fredrik D. Johansson, and David Sontag. 2017. Estimating individual
treatment effect: Generalization bounds and algorithms. In Proc. Int. Conf. Mach.
Learn. Sydney, Australia, 3076–3085.
[43] M. Soyka. 2015. Alcohol Use Disorders in Opioid Maintenance Therapy: Preva-
lence, Clinical Correlates and Treatment. Eur. Addict. Res. 21, 2 (Jan. 2015), 78–87.
[44] Sandra A Springer, P Todd Korthuis, and Carlos Del Rio. 2018. Integrating treat-
ment at the intersection of opioid use disorder and infectious disease epidemics
in medical settings. Ann Intern Med 169, 5 (2018), 335–336.
[45] Xiaogang Su, Chih-Ling Tsai, Hansheng Wang, David M Nickerson, and Bogong
Li. 2009. Subgroup analysis via recursive partitioning. Journal of Machine
Learning Research 10, Feb (2009), 141–158.
[46] Nora D. Volkow and A. Thomas McLellan. 2016. Opioid Abuse in Chronic Pain
— Misconceptions and Mitigation Strategies. N. Engl. J. Med. 374, 13 (2016),
1253–1263.
[47] Tong Wang and Cynthia Rudin. 2017. Causal Rule Sets for Identifying Subgroups
with Enhanced Treatment Effect. arXiv:1710.05426.
[48] Ming Yuan and Yi Lin. 2006. Model Selection and Estimation in Regression with
Grouped Variables. J. R. Stat. Soc. B 68, 1 (2006), 49–67.
[49] Jinghe Zhang, Vijay S. Iyengar, Dennis Wei, Bhanukiran Vinzamuri, Hamsa
Bastani, Alexander R. Macalalad, Anne E. Fischer, Gigi Yuen-Reed, Aleksandra
Mojsilović, and Kush R. Varshney. 2017. Exploring the Causal Relationships
between Initial Opioid Prescriptions and Outcomes. In AMIAWorkshop Data Min.
Med. Informat. Washington, DC, USA.
